Mr. Chris Jackson reports

DOSEOLOGY ANNOUNCES PROPOSED SHARES-FOR-DEBT SETTLEMENT AND RESIGNATION OF DIRECTOR

Doseology Sciences Inc. proposes to issue an aggregate of 75,268 common shares at a deemed price of 18 cents per share to settle $13,548.39 in accrued share-based consulting compensation to a former consultant of the company.

The deemed issue price was determined by reference to the closing price of the company's common shares on the Canadian Securities Exchange on the trading day immediately preceding this announcement in accordance with applicable CSE policies. Subject to the satisfaction of applicable corporate, securities law and CSE requirements, the company anticipates completing the settlement on or about Sept. 30, 2026.

The settlement shares will be subject to the applicable resale restrictions under Canadian securities laws and any hold period imposed under the policies of the CSE.

The company also announces that Daniel Vice has resigned as a director of the company, effective Sept. 17, 2026. The company wishes Mr. Vice well in his future endeavours.

About Doseology Sciences Inc.

Doseology Sciences specializes in pouch-based oral stimulant and cognitive support products. The rapidly expanding oral stimulant pouch sector is gaining momentum as consumers seek modern, discreet alternatives to traditional delivery formats. Unlike combustible tobacco or vape products, oral stimulant pouches are smokeless and vapour-free, providing an alternative delivery method without inhalation.

From a market perspective, the oral-pouch category is experiencing strong global growth as consumers increasingly prioritize convenience, portability and format innovation. The pouch sector represents one of the most dynamic and high-growth areas in modern functional consumer products.

We seek Safe Harbor.